Professor Bob Hancock
Former Associate Faculty
This person is a member of Sanger Institute Alumni.
Bob Hancock's research interests include small cationic peptides as novel antimicrobials and modulators of innate immunity, the development of novel treatments for antibiotic resistant infections, the systems biology of innate immunity, inflammatory diseases and Pseudomonas aeruginosa, and antibiotic uptake and resistance. At the Sanger Institute he is involved in the cellular phenotyping programme, converting mutated mouse embryonic stem cells and human induced pluripotent stem cells into macrophages with the aim of understanding functional networks of genes involved in infections and inflammation.
Bob Hancock is a Professor of Microbiology & Immunology, UBC, and a Canada Research Chair in Health and Genomics. Bob has published more than 660 papers and reviews, has 50 patents awarded, and is an ISI highly cited author in Microbiology with more than 63,000 citations and an h-index of 130. He has won several awards including the Aventis Pharmaceuticals Award, the leading award for research on antimicrobials, and Canada’s three top prizes for Health Research, and is an Officer of the Order of Canada. He was a co-founder of Migenix, Inimex Pharmaceuticals, ABT Innovations, Sepset, and the Centre for Drug Research and Development.
Appointed Associate Faculty at Wellcome Trust Sanger Institute
Director of Genome Canada Grant working with WTSI scientists and a large multi-national team
Appointed Canada Research Chair
Scientific Director of Canadian Bacterial Diseases Network
Appointed Assistant Associate then full Professor at the University of British Colombia